Pyrantel

Exact identity, dog use and dose are supported by current Georgian and Moldovan registrations plus manufacturer instructions; identical-strength EU dog products provide a strong narrower regulatory control. No exact international regulator SPC or public modern assessment supports the much broader Giardia/trematode/prevention claims.

Praziquantel/pyrantel/fenbendazole at 5/14.4/20 mg/kg has a current identical-strength EU dog authorisation for defined mixed GI nematode+cestode stages, so that narrower core is credible. The manufacturer extends one dose to larval stages, Strongyloides, prevention, several trematodes and Giardia without direct exact-product outcomes; a single 20 mg/kg fenbendazole exposure is not a guideline Giardia course.

The manufacturer reports no signs at 3-5x dose and twice-duration exposure in dogs, and the active classes are generally well tolerated. Confidence is limited by no independent exact safety report, broad organ/illness/reproductive exclusions and cholinergic interactions; GI or nonspecific reactions remain possible.

One dose, no fasting, direct/food administration, quarter scoring and individual sachets are convenient. Accurate weighing and deliverable quarter increments remain necessary above 10 kg; repeat/quarterly prevention requires a parasite-risk plan rather than automatic calendar use.

Exact local cat registration and manufacturer directions are corroborated by Moldova; authorised EU cat/dog three-active products exist but differ in fenbendazole strength/presentation. No exact internationally regulated feline bridge or public assessment supports the full extended scope.

Praziquantel and pyrantel support important feline cestode/nematode endpoints, and other regulated cat/dog triple products support class plausibility. However, no exact-composition feline outcome/authorisation bridge validates the one-dose broad larval, Strongyloides, trematode, prevention or Giardia scope; weight bands also create variable exposure in small cats.

The manufacturer explicitly states cats are more overdose-sensitive and may develop depression, vomiting or diarrhoea, without a specific antidote. Quarter-band exposure rises at the low end, and age, periparturient, organ-disease, illness/debilitation and cholinergic-interaction exclusions materially narrow safe use.

One dose, no fasting, food administration and quarter scoring help, including 1-2.5 kg cats. Small-bodyweight bands create relatively large exposure steps, exact quartering/ingestion must be confirmed and feline overdose sensitivity makes rounding or unsupervised repeating unacceptable.

The exact presentation is registered in Georgia (000903, valid to 2030) with a 2024 Russian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence or product-specific study.

Praziquantel and pyrantel pamoate at 1 tablet per 10 kg are well supported against tapeworms including Echinococcus, Toxocara and hookworms, but pyrantel does not cover Trichuris whipworms.

The combination has a wide margin; the label excludes puppies under 3 weeks and animals with marked liver or kidney disease and asks for supervision in pregnancy and lactation, but no independent safety data exist.

Tablets for dogs from 5 kg are simple, but smaller dogs need half a tablet crushed in 5 ml of water and given at 1 ml/kg straight away.

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

The graduated paste supports small-patient dosing and direct oral delivery, but accurate weighing, applicator measurement and complete swallowing remain essential.

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

The graduated paste supports small-patient dosing and direct oral delivery, but accurate weighing, applicator measurement and complete swallowing remain essential.

A current official Czech package leaflet verifies the exact formulation and dose bands, supported by active Georgian veterinary registration (194-11/226-11); independent formulation-specific evidence remains limited.

The three-drug combination supplies broad susceptible nematode and cestode coverage, but outcome depends on parasite diagnosis and label-concordant dosing.

A wide margin is described after overdose, but liver damage, ocular cysticercosis, spinal neurocysticercosis, hypersensitivity and prohibited antiparasitic combinations require patient selection.

Usually single-dose, scored oral administration is workable, but the forte tablet has no labelled dog dose below 2 kg and rounds every started 10 kg above 10 kg.

A current official Czech leaflet verifies the exact feline formulation and dose, supported by active Georgian veterinary registration (194-11/226-11); independent exact-formulation evidence is limited.

The combination offers broad susceptible intestinal nematode and cestode coverage within its narrow labelled feline weight band.

The label reports a wide overdose margin, but the same liver, cysticercosis, hypersensitivity and combination restrictions apply.

A single half-tablet dose is simple for 2-5 kg cats, but no dose is established on this forte label below 2 kg or above 5 kg, materially narrowing practical use.

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

The small scored tablet is useful for puppies, small dogs and cats, but its labelled weight bands are narrow and exact weighing is essential.

The exact formulation is registered in Georgia and supported by a current Czech competent-authority or EU product dossier.

Fenbendazole, pyrantel and praziquantel provide rational broad intestinal nematode and cestode coverage; component and related-combination evidence is established, but robust independent trials of this exact three-drug product are limited.

The labelled safety profile is generally favourable, but piperazine or unplanned anthelmintic overlap, hepatic disease, pregnancy restrictions and dose-band limits require attention.

The small scored tablet is useful for puppies, small dogs and cats, but its labelled weight bands are narrow and exact weighing is essential.

The exact product is registered in Georgia and has a current EU multi-country dossier.

The praziquantel-pyrantel combination has long regulatory use and controlled evidence of high efficacy against susceptible feline cestodes and nematodes, including direct Drontal-combination data.

Adverse effects are generally rare and transient, but kittens under six weeks, pregnancy restrictions, hypersensitivity and piperazine co-administration must be respected.

A scored chewable tablet permits half-tablet dosing and simple single administration after accurate weighing.

The exact three-drug product, current SPC dose table and authorisation are documented in the EU database, with active Georgian veterinary registration (299-11).

The labelled praziquantel-pyrantel-fenbendazole combination provides useful broad coverage of susceptible canine intestinal nematodes and cestodes with a product-specific regimen.

The label-defined restrictions are manageable but relevant: do not use below 4 weeks, with piperazine or in hypersensitive animals; routine antiparasitic stewardship remains necessary.

The palatable chewable tablet can be quartered, given with or without food and is usually administered once across clear weight bands.

The exact product is registered in Georgia (002547) by a Georgian manufacturer with a current distributor instruction, but the registration expires on 2 November 2026, the English text carries a known dosing error and no EU, UK or US authorisation was documented in the reviewed evidence or product study.

Praziquantel and pyrantel are well supported at 1 tablet per 10 kg, but fenbendazole is only 20 mg/kg as a single dose, well below EU single-dose fenbendazole combinations, so its added whipworm and roundworm effect is uncertain.

Pyrantel and fenbendazole are well tolerated and use is allowed from 3 weeks, but the instruction gives no pregnancy guidance and no independent safety data exist.

The Georgian label gives practical bands up to 50 kg, but the 20-30 kg band is missing and quarter-tablet doses for dogs under 2 kg are hard to measure.

The exact strength is actively registered in Georgia and the same-manufacturer current UK Krka Wormer SPC matches the formulation and target species. The public foreign document uses an alternate trade name, slightly reducing exact-brand transparency.

Praziquantel-pyrantel is a mature single-dose feline combination with controlled trial support against susceptible nematodes and cestodes. The label is species- and stage-specific, and reinfection or persistent ascarids may require reassessment rather than unplanned repeat dosing.

Mild transient gastrointestinal or neurologic signs are extremely rare. Pregnancy, kittens under six weeks, weight below 1 kg, hypersensitivity and piperazine or unsupervised dewormer combinations remain important exclusions.

One single scored tablet per 4 kg with half-tablet steps is straightforward from 1-8 kg and can be given directly or in a little food. Dosing outside that range is not established and the tablet is not documented as palatable or crushable.

The exact presentation is actively registered in Georgia. Clinical instructions use the same-manufacturer, same-strength current UK Krka Multiwormer SPC rather than a public document carrying the Dehinel trade name, so exact-brand transparency is one step below Drontal.

The established febantel-pyrantel-praziquantel combination has strong class and field support for susceptible canine intestinal nematodes and cestodes. This exact label is narrower than Drontal Tasty: no whipworm, Echinococcus or Giardia claim should be imported.

Very rare transient gastrointestinal or nonspecific signs are expected, but the first two-thirds of pregnancy, age under two weeks, weight below 2 kg, piperazine, cholinergic and selected interacting drugs require explicit screening.

The flavoured cross-scored tablet supports quarter-tablet dosing from just over 2 kg through 40 kg and can be given directly or with food. It has no labelled dose above 40 kg and should not be extrapolated.

The current AVZ instruction describes a cat-only product, while the Georgian register entry (000694, valid to 2029) lists dogs; no EU, UK or US authorisation was documented in the reviewed evidence and no product-specific study.

Praziquantel and pyrantel are well supported against feline tapeworms and roundworms, and low-dose monthly ivermectin is an established feline heartworm preventive class; product-level dose evidence and bioequivalence are not public.

Ivermectin at preventive doses is well tolerated in cats, but the label bans pregnancy, lactation and other anthelmintics, and no independent safety data exist.

One tablet with the morning feed is simple for deworming, but monthly seasonal heartworm use depends on reliable pilling of cats.

The exact presentation is registered in Georgia (000698, valid to 2029) with a 2017 Russian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence and no product-specific study.

Praziquantel and pyrantel are well supported against tapeworms, Toxocara and hookworms, and low-dose monthly ivermectin is an established heartworm preventive; no component treats Trichuris, and product-level evidence is not public.

Preventive-dose ivermectin is generally tolerated, but in heartworm-positive dogs with many microfilariae it can trigger shock-like reactions, and MDR1-mutant breeds need supervision; pregnancy and lactation are excluded.

A scored tablet with the morning feed and no fasting is practical, but heartworm prevention needs monthly dosing through the mosquito season and a test before starting.

The exact presentation is registered in Georgia (000696, valid to 2029) with a 2017 Russian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence and no product-specific study.

Praziquantel and pyrantel are well supported against tapeworms, Toxocara and hookworms, and low-dose monthly ivermectin is an established heartworm preventive; no component treats Trichuris, and product-level evidence is not public.

Preventive-dose ivermectin is generally tolerated, but in heartworm-positive dogs with many microfilariae it can trigger shock-like reactions, and MDR1-mutant breeds need supervision; pregnancy and lactation are excluded.

A scored tablet with the morning feed and no fasting is practical, but heartworm prevention needs monthly dosing through the mosquito season and a test before starting.

The exact bone-shaped 150/144/50 mg presentation is actively registered in Georgia and has a current exact HPRA SPC plus a multi-country EU authorisation trail.

The full helminth label is supported by recent exact-brand field evidence and longer controlled field data. A small randomized trial supports the three-day Giardia claim, but incomplete clearance in some dogs and diagnostic uncertainty prevent treating every diarrhoeic dog empirically.

Adverse events are very rare and usually mild/transient, but early pregnancy is contraindicated, cholinergic or piperazine combinations can be hazardous, and resistance or underdosing remains possible.

The palatable bone-shaped tablet is voluntarily accepted by most tested dogs, divides into halves, works with or without food and follows a simple 1-tablet/10-kg rule. A retained half is limited to seven days and Giardia requires three doses.

The exact product has a mature current UK/EU regulatory dossier, but an exact Georgian cat-product registration was not found; the former 21-11 mapping was a Frontline product-ID collision.

The praziquantel-pyrantel combination has long regulatory use and controlled evidence of high efficacy against susceptible feline cestodes and nematodes, including direct Drontal-combination data.

Adverse effects are generally rare and transient, but kittens under six weeks, pregnancy restrictions, hypersensitivity and piperazine co-administration must be respected.

A scored film-coated tablet permits half-tablet dosing and single administration, although it is not documented as crushable or flavoured.

The exact strength and presentation are actively registered in Georgia and supported by an exact HPRA SPC. The dossier is transparent, although its cited revision is older than the newest Tasty formulation label.

The three-drug combination has controlled and field evidence against susceptible canine intestinal nematodes and cestodes and the exact label covers adult and selected immature stages. It does not replace diagnosis, risk-based scheduling or intermediate-host control.

Adverse effects are very rare and usually mild/transient, with useful overdose tolerance. Piperazine and cholinergic combinations, pregnancy dosing, hypersensitivity, minimum weight and human Echinococcus risk still require safeguards.

A single flavoured half-tablet-step dose can be given directly or with food without fasting and extends above 40 kg by the labelled 1-tablet/10-kg rule. It is unsuitable below 3 kg and unused parts must be discarded.

The exact product is registered in Georgia (000932, valid to 2030) with a current Ukrainian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence or product-specific study.

Praziquantel and pyrantel pamoate at 1 tablet per 10 kg are well supported against tapeworms including Echinococcus, Toxocara and hookworms, but pyrantel does not cover Trichuris whipworms.

The combination has a wide margin; the label bans the first half of pregnancy and lists transient diarrhoea, salivation or vomiting, but no independent safety data exist.

Scored tablets with clear bands from under 2 kg to 50 kg, given with food or on the tongue, are practical.

The exact product is registered in Georgia for dogs and cats (000932, valid to 2030) with a current Ukrainian manufacturer instruction, but no EU, UK or US authorisation was documented in the reviewed evidence or product-specific study.

Praziquantel with pyrantel is a standard feline combination against Toxocara cati, hookworms and tapeworms, but the catalogue gives fixed quarter or half tablet doses without weight bands, so mg/kg exposure in very small kittens or large cats is uncertain.

Both drugs have wide margins in cats; the label bans the first half of pregnancy and lists transient diarrhoea, salivation or vomiting, but no independent safety data exist.

Quarters of a 0.8 g tablet are hard to split accurately, and many cats resist tablets; it can be hidden in food.

Exact identity, composition, dose and restrictions are transparent in current Georgian and EU regulatory records. Direct combination field evidence and official cross-jurisdiction controls are available; confidence stops below high because the public exact text is old and a modern exact-brand assessment/outcome dossier was not found.

A 235-dog European efficacy population showed approximately 97.2-100% day-7/14/21 control across the principal labelled nematode and cestode endpoints. The complementary mechanisms fit the full spectrum, but benefit remains parasite- and stage-specific: arrested hookworm larvae, reinfection, missed intermediate hosts and resistance can defeat an apparently correct treatment.

The combination is generally well tolerated and supportive FDA pyrantel/praziquantel data show a useful safety margin. Vomiting, diarrhoea and anorexia remain expected signals; bloody diarrhoea/lethargy occurred rarely in comparator field data. Lactation is prohibited, important cholinergic interactions apply and exact-product overdose data are absent.

One oral dose, no fasting and optional food mixing are convenient. The exact label nevertheless authorises one tablet per 10 kg without confirming subdivision, so many small or intermediate-weight dogs lack a deliverable exact dose; accurate weighing, alternative-strength selection, parasite-specific follow-up and environmental/intermediate-host control remain clinical work.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

Every exact strength is registered in Georgia and the combination has current central EU/UK and FDA authorisations with detailed public dossiers.

Large controlled field and laboratory programmes support fleas, ticks, gastrointestinal nematodes and heartworm prevention, with additional labelled mite and lungworm roles; efficacy depends on matching the combined-indication gate and schedule.

The profile is extensively studied but combines isoxazoline neurological risk with macrocyclic-lactone precautions, potential reactions in heavily microfilaraemic dogs and strict dose discipline in MDR1-sensitive breeds.

One palatable monthly chew integrates several parasite targets, but correct use requires heartworm testing where indicated, exact weight-band selection and confirmation that a combination product is clinically justified.

The exact product is registered in Georgia (000962, valid to 2030) and has a Turkish product record naming the marketing-authorisation holder and manufacturer with a full label, but no EU, UK or US authorisation was documented in the reviewed evidence or product-specific study.

It has the Drontal Plus composition at the same 1 tablet per 10 kg, a regimen with strong evidence against roundworms, hookworms, whipworms and tapeworms including Echinococcus; bioequivalence of this generic is not public.

The label is complete: no use below 2 kg, below 4 weeks or in the first two-thirds of pregnancy, clear interaction warnings, and only rare mild vomiting, anorexia or diarrhoea.

Individually sachet-packed tablets with half-tablet bands from 2 to 40 kg, given directly or with food and without fasting, make dosing straightforward.